Cortexolone 17-Alpha Propionate Catalog Description 10mg / ml, 30ml
Cortexolone 17-alpha propionate, also called CB-03-01, is a topical and local competitive anti-androgen produced by Intrepid Therapeutics and Cosmo Pharmaceuticals. Cortexolone 17-alpha propionate was selected for development due to its properties “to treat acne, male pattern baldness, and seborrhoea” without the side-effects of 5-alpha reductase inhibitors or retinoid analogs..
Cortexolone 17-alpha propionate takes effect through a single mechanism to potentially work for treatment of both inflammatory acne and androgenic alopecia. The compound has good penetrative properties but prior to circulating is locally metabolized into a relatively physiologically inert parent molecule, “cortexolone,” meaning the mechanism is both peripheral (not systemic) and selective (for the targeting of the androgen receptor).
In a preliminary but double-blinded trial, cortexolone 17-alpha propionate was more effective than Retin-A for treatment of acne, and also took effect faster:
preliminary data of the trial showed that CB-03-01 met all clinical end points and was clinically superior to placebo and to Retin-A® in the treatment of facial acne vulgaris after 8 weeks of drug application
A major attractive trait of cortexolone 17-alpha propionate/CB-03-01 is that the novel localized AR competitive antagonism does not affect gonadotrophin levels of males, but the compound itself is actually twice as powerful as finasteride in creating an antiandrogenic effect. Cortexolone 17-alpha propionate is unique in the antiandrogen class not just because of its excellent prospective safety profile, but due to its properties allowing for local targeting of sites without increasing circulating or systemic levels of the compound; even when administered subcutaneously, metabolism of the compound prevented systemic effect.
 CB-03-01. Cosmo Pharmaceuticals. Retrieved February 11, 2016.
 CB-03-01 Overview. Intrepid Therapeutics. Retrieved February 11, 2016.
 Tanner, C. (2009, December 11). “Press Releases & Company News.” Cosmo Pharmaceuticals. Retrieved June 10, 2013.
 Trifu, G.-S., et al. Cortexolone 17a-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. British Journal of Dermatology, 2011.
 Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, Nicoletti F. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-6.